
BIOSKETCH



Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS, FARVO
Canada Research Chair (Vision Science)

Leopoldine Wolfe Chair in Translational Vision Research

Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal

Adjunct Professor of Pharmacology, McGill University

Director of Ophthalmology Research, Université de Montréal

Sylvain Chemtob is a reputed neonatal pharmacologist and physiologist, with expertise on mechanisms implicated in ischemic retinopathies and other conditions involving inflammation including preterm labor. He has also initiated a new technology to develop peptidomimetic drugs that target membrane receptors; some compounds are licensed to industry, and one which successfully completed Phase Ib clinical trial is in Phase II (PDC Biotech). His seminal work also triggered the approval (EMA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus, which is now standard of care.

Sylvain Chemtob is author of over 275 articles reported in major journals (*h* index: 60), as well as inventor of 30 patents. He has trained so far 98 students/post-docs (49 graduate students and 37 post-graduate fellows [MDs and PhDs]). He has received numerous awards and is a member of the Canadian Academy of Health Sciences. He holds a Canada Research Chair (Vision Science) and the Leopoldine Wolfe Chair in Translational Research in age-related macular degeneration at Université de Montréal.

ELECTORAL PLATFORM

Platforms for Vision Health Research Network (VHRN):

Pursuit of platforms:

1. Pursuit of excellence of VHRN, and support a spirit of collaboration and unification exemplified by a network.
2. Expand common infrastructures beneficial to members of the VHRN.
3. Continue to assemble an executive committee comprised of youth and experience, in order to maximize innovation advances.

Proposed platforms to develop:

1. Expand vision network across Canada and internationally (academically and through government and non-government agencies); to achieve this goal, integrating a 'networking officer' (eg. Nadia Ben Meriem) would be beneficial; expansion into public health would magnify mission of VHRN (eg. MJ Aubin).
 2. 'Workshops' to facilitate industry-academia partnership (networking) (along the spirit of the GRUM [Groupe de Recherche Universitaire sur le Médicament]).
 3. Promote training of clinician-scientists – put in place a program that allows to establish a partnership between VHNQ and university institutions to support training of clinician-scientists.
 4. Align (relevant) inter-institutional CFI proposals.
 5. Facilitate (financially) access to networks of 'big data' (numerous data bases linked to Ophthalmology and connected fields exist), including imaging.
-